Background: MDC may improve the quality of care for complex diseases. We compared the use of stage-appropriate treatment for lung cancer patients in a co-located MDC to serially-referred (SC) patients within the same healthcare system. Methods: Prospective cohort study of newly-diagnosed lung cancer patients enrolled before onset of treatment from MDC or the standard clinics (SC). Eligible pts had ECOG PS 0-2. Stage-appropriate treatment selection was determined using National Comprehensive Cancer Network (NCCN) guidelines based on clinical stage just before treatment onset. Differences in stage-based treatment rates were calculated using Chi-squared tests. Results: 162 had MDC and 317 SC. Compared to serial care patients, MDC patients were more likely black (37% v 30%) female (51% vs 48%), older (median 69 vs median 66) and less likely commercially insured (36% v 43%). Surgical resection was more frequently used for early stage patients in MDC: 72% v 58% for stage IA/IB (p = 0.2259); 58% v 31% for stage IIA/B and IIIA (T3N1M0) (p = 0.0375). MDC patients also had trends towards higher rates of recommended concurrent chemoradiation therapy for stage IIIA (T4N0-1M0) (75% vs 53%) (p = 0.5835), IIIB (T1-3N3, T4N2) (78% v 68%), but equal rates of concurrent chemoradiation therapy for stage IIIA (T1-3N2M0) (68% vs 68%). Stage IV patientss were more likely to receive chemotherapy or targeted therapy in MDC v SC (87% vs 80%) (p = 0.3795). Conclusions: Lung cancer patients in the MDC model are more likely to receive recommended stage-appropriate treatment than those in the usual serial care model, despite relatively adverse demographic characteristics. Clinical trial information: NCT02123797